-
Epiprobe company won the title of “Specia...
Recently, Shanghai Municipal Commission of Economy and Information Technology announced the list of Shanghai small and medium-sized enterprises which are specialization, refinement, distinctiveness and novelty (second batch) in 2022. Shanghai Epiprobe Biotechnology Co., Ltd. relies on its experti...Read more -
The Urothelial Cancer Detection Kit was recogni...
Early May 2023, TAGMe DNA Methylation Detection Kit(qPCR) for Urothelial Cancer independently developed by Shanghai Epiprobe Biotechnology Co., Ltd, obtained “Breakthrough Device Designation” from US FDA. US FDA Breakthrough Devices Program aims to ensure promoting the a...Read more -
TAGMe DNA Methylation Detection Kits (qPCR) for...
Solution for endometrial cancer, eliminating cancer at the stage of precancerous lesions. Endometrial cancer is one of the three major malignant cancers in gynecology. Endometrial cancer is one of the most common malignant cancers in the female reproductive system, ranki...Read more -
Epiprobe’s pan-cancer biomarker followed ...
The “Angel Project” assists precision medical poverty alleviation. On February 19, 2023, the Central Committee of the Chinese People’s Political Consultative Conference (CPPCC) and Siemens jointly launched the Guardian Angel Project in Gansu Province, donating advanced equipment...Read more -
Epiprobe has successfully passed the ISO13485 Q...
Reliable and stable products are the lifeline of a company. Since its establishment nearly 5 years ago, Epiprobe has always put quality first, providing users with high-quality and reliable cancer early screening products. On May 9, 2022, after a rigorous review by exper...Read more -
Baidu Health and Epiprobe cooperatively advance...
Oct. 30, 2022, Baidu Health Internet Hospital (referred as "Baidu Health") and Shanghai Epiprobe Biotechnology Co., Ltd. (referred as "Epiprobe") has announced strategic cooperation to popularize the early pan-cancer screening in clinical and general health channels duri...Read more -
Epiprobe’s three cancer methylation detection k...
On May 8, 2022, Epiprobe announced that its independently developed three cancer gene methylation detection kits: TAGMe DNA Methylation Detection Kits (qPCR) for Cervical Cancer, TAGMe DNA Methylation Detection Kits (qPCR) for End...Read more -
Epiprobe completed nearly RMB 100 million of Se...
In recent, Shanghai Epiprobe Biotechnology Co., Ltd. (refer as "Epiprobe") announced that it had completed nearly RMB 100 million in Series B financing, which is jointly invested by industrial capital, government investment platfor...Read more
